Danaher news
The WiseView Research desk's stories that name Danaher, the latest headlines about it, and the trades members of Congress and company insiders have disclosed. The DHR page →
- HeadlineDanaher (DHR) Upgraded to Buy: Here's Why
- HeadlineLH vs. DHR: Which Stock Is the Better Value Option?
- HeadlineDanaher Q3 Recap: Decent Results, Still A Hold
- HeadlineWhy Danaher Stock Bounced Higher Today
- HeadlineDanaher Corporation (DHR) Q3 2026 Earnings Call Transcript
- HeadlineDanaher: 3 Key Takeaways for Long-Term Investors
- HeadlineDanaher Corp (DHR) (Q3 2026) Earnings Call Highlights: Core Growth Accelerates to 5.5% Ex-Respiratory as EPS Guidance Rises
- HeadlineDanaher Q3 Review: Interested To See What The New Management Will Bring
- HeadlineDHR Q3 Earnings Beat on Biotechnology Strength, Sales in Line
- HeadlineDanaher Beats Profit Estimates, Raises Outlook as Customer Demand Improves
- HeadlineDanaher Q3 Earnings Call Highlights
- HeadlineDanaher (DHR) Reports Q3 Earnings: What Key Metrics Have to Say
- HeadlineDanaher (DHR) Tops Q3 Earnings and Revenue Estimates
- HeadlineDanaher Reports Third Quarter 2026 Results
- HeadlineDanaher Corporation $DHR Stock Holdings Lowered by Louisbourg Investments Inc.
- HeadlineDanaher Gears Up to Post Q3 Earnings: What Lies Ahead for the Stock?
- HeadlineSeeking Clues to Danaher (DHR) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
- HeadlineThese 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
- HeadlineWill Danaher (DHR) Beat Estimates Again in Its Next Earnings Report?
- HeadlineDanaher (DHR) Earnings Expected to Grow: Should You Buy?
- HeadlineHow to Invest in AI Drug Discovery
- HeadlineDanaher Collaborates with NVIDIA to Advance Autonomous Science
- HeadlineDanaher Announces Appointments of Daniel Comas and Robert Hershberg to Board of Directors
- HeadlineDanaher Accelerates Life Sciences Research with New AI-powered Autonomous Lab
- HeadlineELV or DHR: Which Is the Better Value Stock Right Now?
- HeadlineJulie Sawyer Montgomery Assumes Role as Danaher President and Chief Executive Officer
- HeadlineDHR's Growth Backed by Strong Biotechnology Unit: Can It Maintain the Pace?
- HeadlineThe Top HealthTech Questions Landing on Our Desks
- CongressKevin Hern sold $15,001 - $50,000 of DHR
- CongressKevin Hern sold $1,001 - $15,000 of DHR
- CongressMichael McCaul bought $1,001 - $15,000 of DHR
- CongressMichael McCaul bought $1,001 - $15,000 of DHR
- CongressMichael McCaul bought $1,001 - $15,000 of DHR
- CongressMichael McCaul bought $1,001 - $15,000 of DHR
- CongressRo Khanna bought $15,001 - $50,000 of DHR
- CongressMichael McCaul bought $1,001 - $15,000 of DHR
Headlines link to their publishers. Members of Congress disclose ranges, not exact amounts, and may file weeks after the trade; insider filings are open-market purchases and sales from SEC Form 4. For information only, not investment advice.